A single-center cytogenetic study of 629 Chinese patients with de novo acute myeloid leukemia-evidence of major ethnic differences and a high prevalence of acute promyelocytic leukemia in Chinese patients

Cancer Genetics

Volumn 204, Issue 8, 2011, Pages 430-438

  So, Chi Chiu ^a   Wan, Thomas S ^a   Chow, Jessica L ^b   Hui, Koon Chun ^a   Choi, William W ^a   Lam, Clarence C ^a   Chan, Li Chong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute myeloid leukemia; Acute promyelocytic leukemia; Chinese; Cytogenetics; Prevalence

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; CANCER GROWTH; CANCER PROGNOSIS; CHILD; CHINESE; CHROMOSOME 11Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION 5; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION 11; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; INFANT; JAPANESE; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHENOTYPIC VARIATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; ASIAN; CHINA; CLINICAL TRIAL; ETHNIC GROUP; ETHNOLOGY; GENETICS; MIDDLE AGED; PREVALENCE; PROGNOSIS; SECOND CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; CHINA; ETHNIC GROUPS; FEMALE; HUMANS; INFANT; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PREVALENCE; PROGNOSIS; YOUNG ADULT;

EID: 84856380385     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.06.003     Document Type: Article

References (34)

1. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of haematopoietic and lymphoid tissue 2008, IARC, Lyon.
2. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
3. Ravindranath Y., Chang M., Steuber C.P., et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005, 19:2101-2116.
4. Byrd J.C., Mrózek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
5. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625.
6. Bennett J.M., Catovsky D., Daniel M.T., et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:460-462.
7. Chan L.C., Kwong Y.L., Liu H.W., et al. Cytogenetic analysis of hematologic malignancies in Hong Kong. A study of 98 cases. Cancer Genet Cytogenet 1992, 62:154-159.
8. Shaffer L.G., Slovak M.L., Campbell L.J. ISCN: an international system for human cytogenetic nomenclature 2009, S. Karger, Basel.
9. Nakase K., Bradstock K., Sartor M., et al. Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult cases. Leukemia 2000, 14:163-168.
10. Grimwade D., Hills R.K., Moorman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
11. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
12. Cheng Y., Wang Y., Wang H., et al. Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China. Leukemia 2009, 23:1801-1806.
13. Harrison C.J., Hills R.K., Moorman A.V., et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010, 28:2674-2681.
14. von Neuhoff C., Reinhardt D., Sander A., et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010, 28:2682-2689.
15. Betts D.R., Ammann R.A., Hirt A., et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukemia. A study of the Swiss Pediatric Oncology Group (SPOG). Eur J Haematol 2007, 78:468-476.
16. Smith F.O., Alonzo T.A., Gerbing R.B., et al. Long-term results of children with acute myeloid leukemia: a report of three consecutive phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005, 19:2054-2062.
17. Perel Y., Auvrignon A., Leblanc T., et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group. Leukemia 2005, 19:2082-2089.
18. Stark B., Jeison M., Gabay L.G., et al. Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukemia: report from a referral center in Israel. Br J Haematol 2004, 126:320-327.
19. Forestier E., Heim S., Blennow E., et al. Cytogenetic abnormalities in childhood acute myeloid leukemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. Br J Haematol 2003, 121:566-577.
20. Tong H., Lu C., Zhang J., et al. Immunophenotypic, cytogenetic and clinical features of 192 AML patients in China. Clin Exp Med 2009, 9:149-155.
21. Tien H.F., Wang C.H., Lin M.T., et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995, 84:60-68.
22. Wan T.S., So C.C., Hui K.C., et al. Diagnostic utility of dual fusion PML/RARalpha translocation DNA probe (D-FISH) in acute promyelocytic leukemia. Oncol Rep 2007, 17:799-805.
23. Lit B.M., Wong K.F., Kwong Y.L. Rearrangement of the myeloid-lymphoid leukemia gene in Hong Kong Chinese children with acute leukemia. Hong Kong Med J 2001, 7:9-14.
24. Chan N.P., Wong W.S., Ng M.H., et al. Childhood acute myeloid leukemia with CBFbeta-MYH11 rearrangement: study of incidence, morphology, cytogenetics, and clinical outcomes of Chinese in Hong Kong. Am J Hematol 2004, 76:300-303.
25. Douer D., Preston-Martin S., Chang E., et al. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996, 87:308-313.
26. de Salvo L., Weir Medina J., Gomez Sanchez O., et al. Acute promyelocytic leukemia in the west of Venezuela. Sangre (Barcelona) 1989, 34:329-331.
27. Malta Corea A., Pacheco Espinoza C., Cantù Rajnoldi A., et al. Childhood acute promyelocytic leukemia in Nicaragua. Ann Oncol 1993, 4:892-894.
28. Douer D., Santillana S., Ramezani L., et al. Acute promyelocytic leukemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARalpha fusion gene. Br J Haematol 2003, 122:563-570.
29. Dong S., Geng J.P., Tong J.H., et al. Breakpoint clusters of the PML gene in acute promyelocytic leukemia: primary structure of the reciprocal products of the PML-RARA gene in a patient with t(15;17). Genes Chromosomes Cancer 1993, 6:133-139.
30. Gallagher R.E., Willman C.L., Slack J.L., et al. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997, 90:1656-1663.
31. Biondi A., Luciano A., Bassan R., et al. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint. Leukemia 1995, 9:1461-1466.
32. Sanz M.A., Lo Coco F., Martín G., et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000, 96:1247-1253.
33. Hasan S.K., Mays A.N., Ottone T., et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008, 112:3383-3390.
34. Mays A.N., Osheroff N., Xiao Y., et al. Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood 2010, 115:326-330.